Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated:  2/17/2016
University of Alberta
mi
from
Edmonton,
IGIV Study for Chronic ITP Patients Ages 3-70
A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura
Status: Enrolling
Updated: 2/17/2016
University of Alberta
mi
from
Edmonton,
Click here to add this to my saved trials
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
A Phase II Study of Twice Daily Cytarabine and Fludarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Status: Enrolling
Updated:  2/17/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
A Phase II Study of Twice Daily Cytarabine and Fludarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Status: Enrolling
Updated: 2/17/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
La Jolla, CA
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Rochester, MN
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
St Louis, MO
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Houston, TX
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated:  2/17/2016
mi
from
Clayton,
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea
Status: Enrolling
Updated: 2/17/2016
mi
from
Clayton,
Click here to add this to my saved trials
Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures
Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles - A Quality Improvement Theragnostic Stewardship Project
Status: Enrolling
Updated:  2/17/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures
Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles - A Quality Improvement Theragnostic Stewardship Project
Status: Enrolling
Updated: 2/17/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
The University of California, San Diego
mi
from
La Jolla, CA
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Stanford University
mi
from
Palo Alto, CA
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
University of Florida
mi
from
Gainesville, FL
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Johns Hopkins University
mi
from
Baltimore, MD
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
University of Michigan at Ann Arbor
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
University of Minnesota Twin Cities
mi
from
Minneapolis, MN
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
University of Minnesota Twin Cities
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Sloan-Kettering Institute for Cancer Research
mi
from
New York, NY
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Sloan-Kettering Institute for Cancer Research
mi
from
New York, NY
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Duke University
mi
from
Durham, NC
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated:  2/17/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Blood and Marrow Transplant Clinical Research Network
Blood and Marrow Transplant Clinical Research Network
Status: Enrolling
Updated: 2/17/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
La Jolla, CA
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Stanford, CA
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Boston, MA
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Rochester, MN
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated:  2/17/2016
Clinical Research Facility
mi
from
Houston, TX
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
Status: Enrolling
Updated: 2/17/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2 Study of Planned Donor Lymphocyte Infusion After Reduced Intensity Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  2/18/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2 Study of Planned Donor Lymphocyte Infusion After Reduced Intensity Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 2/18/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
A Phase I/II Clinical Trial of Pomalidomide With Melphalan and Dexamethasone in Patients With Newly Diagnosed Untreated Systemic AL Amyloidosis
Status: Enrolling
Updated:  2/18/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
A Phase I/II Clinical Trial of Pomalidomide With Melphalan and Dexamethasone in Patients With Newly Diagnosed Untreated Systemic AL Amyloidosis
Status: Enrolling
Updated: 2/18/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
Status: Enrolling
Updated:  2/19/2016
UCLA Medical Center
mi
from
Los Angeles, CA
PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
Status: Enrolling
Updated: 2/19/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
Status: Enrolling
Updated:  2/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
Status: Enrolling
Updated: 2/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
Status: Enrolling
Updated:  2/19/2016
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
Status: Enrolling
Updated: 2/19/2016
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Click here to add this to my saved trials
PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
Status: Enrolling
Updated:  2/19/2016
New York Weill Cornell Medical Center
mi
from
New York, NY
PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3
Status: Enrolling
Updated: 2/19/2016
New York Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia
Status: Enrolling
Updated:  2/20/2016
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia
Status: Enrolling
Updated: 2/20/2016
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/22/2016
UCSD Medical Center, Thornton Hospital
mi
from
La Jolla, CA
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/22/2016
UCSD Medical Center, Thornton Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/22/2016
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/22/2016
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/22/2016
Indiana Blood and Marrow Transplantation Clinic
mi
from
Indianapolis, IN
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/22/2016
Indiana Blood and Marrow Transplantation Clinic
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/22/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/22/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/22/2016
Univ of Washington
mi
from
Seattle, WA
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/22/2016
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/22/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML
A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/22/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  2/25/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 2/25/2016
University of Kansas Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  2/25/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 2/25/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  2/26/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 2/26/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials